Bausch + Lomb Corporation - BLCO STOCK NEWS

Bausch + Lomb (NYSE/TSX: BLCO) has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) using an excimer laser. The acquisition strengthens BLCO's glaucoma portfolio by introducing a differentiated treatment approach that can be performed alongside cataract surgery.

The ELIOS system offers a tissue-friendly, non-thermal laser-based procedure for glaucoma, which is expected to see a 47% prevalence increase from 2020 to 2040. The technology is currently CE marked and available in the European Union, with FDA approval pending. Over 19% of cataract surgery patients also have glaucoma or ocular hypertension, presenting an opportunity for concurrent treatment.

Bausch + Lomb (NYSE/TSX: BLCO) announced significant achievements in its recycling initiatives, with its ONE by ONE Recycling and Biotrue Eye Care Recycling programs collecting over 94 million units (569,743 pounds) of used contact lenses, eye care, and lens care materials in the United States. This recycling effort addresses a important environmental concern, as an estimated 6-10 metric tons of contact lenses end up in wastewater annually in the US. The programs, operated in collaboration with TerraCycle, help prevent these materials from ending up in landfills or waterways, where they could potentially impact aquatic environments and the human food supply.

Bausch + Lomb (NYSE/TSX: BLCO) reported strong Q3 2024 results with total revenue of $1.196 billion, up 19% year-over-year. The company achieved growth across all segments: Vision Care revenue reached $684 million (+6%), Surgical revenue hit $206 million (+11%), and Pharmaceuticals revenue grew to $306 million (+76%). GAAP Net Income was $4 million, compared to a net loss of $84 million in Q3 2023. Adjusted EBITDA increased to $212 million. Based on strong performance, the company raised its full-year 2024 revenue guidance to $4.725-$4.825 billion.

Bausch + Lomb (NYSE/TSX: BLCO) has received FDA approval for the enVista® Envy™ full range of vision intraocular lens (IOL). This new IOL offers a continuous range of vision with excellent dysphotopsia tolerance on the enVista IOL platform.

Key findings from clinical trials include:

• 86% of patients reported little to no bothersomeness for dysphotopsia
• 94% of patients reported little to no difficulty viewing close objects
• 93% were completely to moderately satisfied with their vision post-surgery

The enVista Envy IOL features ActivSync Optic intelligent energy distribution for optimal vision in various lighting conditions. It also allows surgeons to treat a wider range of astigmatic patients with more accuracy. The product will be available on a basis in the coming weeks and more broadly in 2025.

Bausch + Lomb (NYSE/TSX: BLCO), a leading global eye health company, has announced it will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update.

Interested parties can access the webcast through the provided link or join via phone using the specified dial-in numbers. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the call. A replay of the call will be available until November 13, 2024, using the provided replay dial-in numbers and passcode.

Bausch + Lomb (NYSE/TSX: BLCO) has launched Opal, a digital e-commerce marketplace in the United States. This platform is designed to streamline the ordering process for Bausch + Lomb contact lenses and select over-the-counter products, aiming to maximize efficiencies for eye care practices and enhance patient experience.

Key features of Opal include:

• Complimentary offering for eye care professionals
• Order tracking and history
• Appointment and prescription reminders
• Free shipping to patients' homes or practices
• Integration with Bausch + Lomb Horizon Rewards loyalty program

The platform simplifies administrative tasks, inventory management, and cost comparisons, potentially freeing up resources and staff time for eye care practices while supporting business growth.

Bausch + Lomb (NYSE/TSX: BLCO) reported strong Q2 2024 results with revenue of $1.216 billion, up 17% as reported and 20% on a constant currency basis compared to Q2 2023. The company experienced broad-based growth across all business segments. Key highlights include:

- Vision Care revenue: $697 million, up 8% (11% constant currency)
- Surgical revenue: $209 million, up 7% (9% constant currency)
- Pharmaceuticals revenue: $310 million, up 60% (61% constant currency)

However, the company reported a GAAP net loss of $151 million. Adjusted EBITDA (non-GAAP) was $209 million, up from $179 million in Q2 2023. Based on strong performance, Bausch + Lomb raised its full-year 2024 revenue and Adjusted EBITDA guidance.

Bausch + Lomb (NYSE/TSX: BLCO), a prominent global eye health company, is set to release its second-quarter 2024 financial results on July 31, 2024. The company will hold a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All relevant materials will be available on the Investor Relations section of the Bausch + Lomb website before the call. The webcast can be accessed via the provided link, and participants can join the call using the provided dial-in numbers and access code. A replay will be available until August 14, 2024.

Bausch + Lomb (NYSE/TSX: BLCO) revealed results from their inaugural State of Dry Eye survey, highlighting widespread dry eye symptoms among Americans and a lack of awareness about the condition. The survey underscores that dry eye is increasingly prevalent, particularly among younger individuals due to modern lifestyles and extensive digital device use. Key findings include that 75% of sufferers find symptoms extremely bothersome, and 67% have had to alter their daily activities. Despite these impacts, 70% of Americans are unaware of prevention or treatment options, and 43% do not regularly see an eye doctor. To address this, Bausch + Lomb launched KnowYourDryEye.com to provide education and facilitate dialogues between sufferers and eye care professionals. Untreated dry eye can worsen and lead to more serious eye problems, making awareness and early intervention crucial.